Scientific Publications and Presentations
Ovarian Cancer Abstracts and Presentations
For a copy of the presentations listed below, please email medinfo@pharmaand.com
Exploratory PFS Results for the ATHENA Study as Maintenance Treatment Following Frontline Platinum-based Chemotherapy in Ovarian Cancer in the Context of ATHENA-MONO and ATHENA-COMBO Results.
Authors: Fehm TN, Kristeleit RS, Schneeweiss A, et al.
Congress: International Charité Mayo Conference. 7-10 May 2025. Berlin, Germany.
ATHENA-MONO Post-progression Survival Data Update in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Authors: Ghamande S, Miller RE, Solovyeva E, et al.
Congress: ESGO Congress. 20-23 February 2025. Rome, Italy.
ATHENA-COMBO, a Phase 3, Randomized Trial Comparing Rucaparib + Nivolumab Combination Therapy vs Rucaparib Monotherapy as Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer.
Authors: Monk BJ, Oaknin A, O’Malley DM, et al.
Congress: ESMO Congress. 13-17 September 2024. Barcelona, Spain.
Abstract: Annals of Oncology
Updated Progression-Free Survival in Patients with Newly Diagnosed Advanced Ovarian Cancer Treated with Rucaparib in ATHENA-MONO.
Authors: Kristeleit RS, O’Malley DM, Lim MC, et al.
Congress: ESMO Gynaecological Cancers Annual Meeting. 20-22 June 2024. Florence, Italy.
Abstract: ESMO Open
Final Safety Results From ATHENA–MONO (GOG-3020/ENGOT-ov45), a Randomized, Placebo-controlled, Double-blind, Phase 3 Trial Evaluating Rucaparib Monotherapy as Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer.
Authors: O’Malley DM, Monk BJ, Lim MC, et al.
Congress: ASCO Annual Meeting. 31 May – 4 June 2024. Chicago, IL
Abstract: Journal of Clinical Oncology
Interim Post-progression Data and Updated Survival in Patients with Newly Diagnosed Advanced Ovarian Cancer in ATHENA-MONO.
Authors: Kristeleit RS, O’Malley DM, Lim MC, et al.
Congress: SGO Annual Meeting. 16-18 March 2024. San Diego, CA
Abstract: Gynecologic Oncology
Ovarian Cancer Manuscripts
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Authors: Monk BJ, Parkinson C, Lim MC, et al.
J Clin Oncol. 2022: 40(34):3952-64.
doi: 10.1200/JCO.22.0100
ATHENA (GOG-3020/ENGOT-ov45): A Randomized Phase III Trial to Evaluate Rucaparib as Monotherapy (ATHENA-MONO) And Rucaparib in Combination with Nivolumab (ATHENA-COMBO) as Maintenance Treatment Following Frontline Platinum-based Chemotherapy in Ovarian Cancer.
Authors: Monk BJ, Coleman RL, Fujiwara K, et al.
Int J Gynecol Cancer. 2021: 31(12):1589-94.
doi: 10.1136/ijgc-2021-002933
Prostate Cancer Presentations
For a copy of the presentations listed below, please email medinfo@pharmaand.com
Impact of Germline vs Somatic BRCA Mutation Status on the Efficacy of Rucaparib vs Physician’s Choice in the TRITON3 Study of Patients with Metastatic Castration-Resistant Prostate Cancer.
Authors: Chowdhury S, Bryce AH, Fizazi K, et al.
Congress: ASCO Annual Meeting. 30 May – 3 June 2025. Chicago, IL.
Rucaparib vs Docetaxel or Second-generation Androgen Receptor Pathway Inhibitor Therapy for Metastatic Castration-Resistant Prostate Cancer Patients with BRCA Mutations with or Without Liver Metastases in TRITON3.
Authors: Morris D, Bryce AH, Piulats J, et al.
Congress: AUA Annual Meeting. 26-29 April 2025. Las Vegas, NV.
Abstract: The Journal of Urology
Rucaparib vs Docetaxel (DTX) or Second-generation Androgen Pathway Inhibitor (ARPI) Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Final Overall Survival (OS) and Safety.
Authors: Bryce AH, McDermott R, Piulats J, et al.
Congress: ASCO Genitourinary Cancers Symposium. 26-28 February 2025. San Francisco, CA.
Abstract: Journal of Clinical Oncology
Prostate Cancer Manuscripts
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer.
Authors: Fizazi K, Piulats JM, Reaume MN, et al.
N Engl J Med. 2023: 388(8):719-32.
doi: 10.1056/NEJMoa2214676.